Table 2:
Comparison of demographic and baseline characteristics among metabolizer groups
| Poor or Intermediate Metabolizers (n=33) | Normal or Ultrarapid Metabolizers (n= 224) | P* value | |
|---|---|---|---|
|
Frequency (%) or median (IQR) |
|||
| Age at risperidone commencement (years) | 8.9 (6.2-10.6) | 8.3 (6.3-10.5) | 0.9 |
| Male Sex | 25 (75.8) | 163 (72.8) | 0.8 |
| Race | 0.5 | ||
| African-American | 5 (15.2) | 24 (10.7) | |
| Asian/Pacific islander | 1 (3) | 4 (1.8) | |
| Caucasian | 26 (78.8) | 191 (85.3) | |
| Unknown | 1 (3) | 4 (1.8) | |
| Native American | 0 | 1 (0.5) | |
| Ethnicity | 0.4 | ||
| Hispanic | 1 (3) | 5 (2.2) | |
| Non-Hispanic | 31 (93.9) | 215 (96) | |
| Unknown | 1 (3) | 4 (1.8) | |
| Presence of comorbid conditions | 0.8 | ||
| No | 21 (63.6) | 146 (65.2) | |
| Yes | 12 (36.4) | 78 (34.8) | |
| Specific comorbidities | |||
| Seizure disorder | 8 (24.2) | 31 (13.8) | 0.1 |
| Asthma | 2 (6.1) | 21 (9.4) | 0.7 |
| Attention deficit hyperactivity disorder | 13 (39.4) | 101 (45) | 0.6 |
| Autism | 10 (30.3) | 61 (27.2) | 0.7 |
| Specific indication for risperidone | |||
| Aggression | 18 (54.5) | 107 (47.8) | 0.6 |
| Behavioral problems | 13 (39.4) | 66 (29.5) | 0.3 |
| Agitation | 4 (12.1) | 38 (17) | 0.6 |
| Irritability | 5 (15.2) | 58 (25.9) | 0.2 |
| Self-injurious behaviors | 6 (18.2) | 39 (17.4) | 0.5 |
| Baseline dosing regimen of risperidone (mg/day) | 0.8 (0.3-1) | 0.5 (0.5-1) | 0.9 |
| Dose modification | 0.4 | ||
| Yes | 13 (39.4) | 109 (48.7) | |
| No | 20 (60.6) | 115 (51.3) | |
| Adverse Events | 15 (45.5) | 61 (27.2) | 0.04 |
*
P values for slow versus extensive metabolizers from Kruskal-Wallis test for continuous variables and Fisher’s exact for categorical variables. IQR – Interquartile Range